High EGFR Expression Associated With Decreased Adjuvant Trastuzumab Benefit in Some Patients With HER2+ Invasive Breast Cancer

Capsule Summary - EGFR expression over 13 ng/µg as measured by a novel antibody-based quantitative immunofluorescence tissue microarray negatively affected the clinical benefit of trastuzumab given concurrently (as opposed to sequentially) with chemotherapy in a cohort of patients from the NCCTG N9831 trial.
Source: Clinical Care Options Oncology - Breast Cancer - Category: Cancer & Oncology Source Type: research